Novel chimerized IgA CD20 antibodies: Improving neutrophil activation against CD20-positive malignancies

• Príomhchruthaitheoirí: Mitchell Evers (Údar), Toine Ten Broeke (Údar), J.H. Marco Jansen (Údar), Maaike Nederend (Údar), Firas Hamdan (Údar), Karli R. Reiding (Údar), Saskia Meyer (Údar), Petra Moerer (Údar), Iris Brinkman (Údar), Thies Rösner (Údar), Robert Jan Lebbink (Údar), Thomas Valerius (Údar), Jeanette H.W. Leusen (Údar)
• Formáid: LEABHAR
• Foilsithe / Cruthaithe: Taylor & Francis Group, 2020-01-01T00:00:00Z.
• Ábhair: article
• Rochtain ar líne: Connect to this object online.

Current combination therapies elicit high response rates in B cell malignancies, often using CD20 antibodies as the backbone of therapy. However, many patients eventually relapse or develop progressive disease. Therefore, novel CD20 antibodies combining multiple effector mechanisms were generated. T...